ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1334

Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

Dalifer Freites Nuñez1, Leticia León 2, Marta Redondo 3, Cristina Vadillo Font 4, Pia Lois 5, Arkaitz Mucientes Ruiz 4, Luis Rodríguez-Rodríguez 6, Benjamín Fernández Gutiérrez 7, Juan Angel Jover Jover 4 and lydia Abasolo Alcazar 4, 1Hospital Clínico San Carlos, MADRID, Spain, 2Fundación para la Investigación Biomedica, Madrid, Madrid, Spain, 3Universidad Camilo José Ceja, Madrid, Madrid, Spain, 4HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, 5Hospital Clínico San Carlos, Madrid, Madrid, Spain, 6Fundación para la Investigación Biomedica, Madrid, Spain, 7Hospital Clínico San Carlos, Madrid

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biologic agents and PROM, DMARDs, Fatigue, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Fatigue is one of the most frequent symptoms in patients with rheumatoid arthritis (RA), affecting more than 80% of them. The experience of fatigue is multidimensional. Purpose: to identify the factors associated with fatigue on its different subscales (Physical, Living, Cognitive and Emotional).

Methods: Cross-sectional study. 79 patients were included, patients were being followed up in the rheumatology outpatient clinic of Hospital Clínico San Carlos, Madrid, Spain. Data were collected between July 2018 and May 2019. All patients met the ACR/EULAR 2010 criteria and they were in treatment with Biological agent (anti-TNF and Non anti-TNF) or Targeted Synthetic DMARD (jakinibs).  Main variable: Fatigue was assessed by the multidimensional fatigue scales, the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ). Covariables: Sociodemographic, Disease-related variables, clinical and treatment. Statistical analysis. A descriptive analysis was carried out for the different variables. To identify factors independently associated to BRAF-MDQ and its subscales, multivariable linear regression was applied. Results were expressed as coef with their corresponding 95% CI. A value of p < 0.05 was accepted as statistically significant.

Results: A total of 79 patients were evaluated, 66 were females (83%), the mean age (SD) was 56.64(11.63) years old and mean disease duration (SD) was 14.81 (7.60) years. RF was positive in 54% of patients. 67% of the patients were in active on work status and 22% were retired. Regarding comorbidities, 42% had dyslipidemia, 43% hypertension, 14% hypothyroidism and 15% depression. DAS28-ESR and SDAI mean scores of the patients were 2.63 (0.94), 8.54 (6.30) respectively. HAQ mean (SD) was 0.88 (0.64) and the rest of the clinical, treatment characteristics, and the scores of the fatigue instruments are shown in Table 1. The factors affecting the BRAF-MDQ and its different subscales was evaluated in multivariate analyze Table 2. Our results shows a correlation between disability and the different dimensions of the BRAF-MDQ (p < 0.001). Patients who reported good sleep quality had less physical and living fatigue. Age and male sex was negatively associated with physical fatigue, besides a positive RF was associated with less physical and living fatigue. In addition, an association between depression and cognitive fatigue was observed. Different disease activity index and treatments did not result statistical significance in the final multivariate model.

Conclusion: It is important to evaluate fatigue in a multidimensional perspective, each of the different subscales could be modulated by different factors. The results of our study indicated that disability predicts in all subscales of fatigue, however, other factors can configure different patterns of fatigue in RA patients, and identify them is key to the approach of this complex symptom.


Table 1. Characteristics of the study group.

Table 1. Characteristics of the study group.


Table 2. Multivariate analyses of BRAF-MDQ and its subscales

Table 2. Multivariate analyses of BRAF-MDQ and its subscales.


Disclosure: D. Freites Nuñez, None; L. León, None; M. Redondo, None; C. Vadillo Font, None; P. Lois, None; A. Mucientes Ruiz, None; L. Rodríguez-Rodríguez, None; B. Fernández Gutiérrez, None; J. Jover Jover, None; l. Abasolo Alcazar, None.

To cite this abstract in AMA style:

Freites Nuñez D, León L, Redondo M, Vadillo Font C, Lois P, Mucientes Ruiz A, Rodríguez-Rodríguez L, Fernández Gutiérrez B, Jover Jover J, Abasolo Alcazar l. Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/patterns-of-fatigue-in-rheumatoid-arthritis-patients-who-received-biological-and-targeted-synthetic-disease-modifying-antirheumatic-drugs/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patterns-of-fatigue-in-rheumatoid-arthritis-patients-who-received-biological-and-targeted-synthetic-disease-modifying-antirheumatic-drugs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology